A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Klupp, Nerida L ^a   Kiat, Hosen ^b,c,d   Bensoussan, Alan ^a   Steiner, Genevieve Z ^a   Chang, Dennis H ^a  

^a WESTERN SYDNEY UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PLANT EXTRACT;

AGED; AUSTRALIA; CARDIOVASCULAR DISEASE; CHEMISTRY; CONTROLLED STUDY; CORDYCEPS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; GANODERMA LUCIDUM; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; CORDYCEPS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; MALE; METABOLIC SYNDROME; MIDDLE AGED; PLANT EXTRACTS; PROSPECTIVE STUDIES; REISHI; TREATMENT OUTCOME;

EID: 84982165956     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29540     Document Type: Article

References (62)

1. World Health Organization, Cardiovascular diseases. (2011a) Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. (Accessed: 31st May 2016).
2. Australian Institute of Health and Welfare, Prevention of cardiovascular disease, diabetes and chronic kidney disease: Targeting risk factors. (2009b) Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id= 6442459914. (Accessed: 31st May 2016).
3. Graham, I. et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. European Journal of Cardiovascular Prevention and Rehabilitation. 28(19), 2375-2414 (2007).
4. Heart Foundation, & National Stroke Foundation. Time for action: a national plan to reduce the burden of cardiovascular disease-Australia's biggest killer (2008). Melbourne, Australia: National Heart Foundation of Australia, National Stroke Foundation of Australia.
5. World Heart Federation, Cardiovascular disease risk factors. (2016) Available at: http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/. (Accessed: 31st May 2016).
6. Reaven, G. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes. 37, 1595-1607 (1988).
7. Alberti, K. G., Zimment, P. & Shaw, J. The metabolic syndrome: A new worldwide defnition. Lancet. 366, 1059-1061 (2005).
8. World Health Organization, Prevention of cardiovascular disease: Guidelines for assessment and management of cardiovascular disease. (2007) Available at: http://www.who.int/cardiovascular-diseases/guidelines/Full%20text.pdf. (Accessed: 31st May 2016).
9. US Centres for Disease Control and Prevention, National Diabetes Fact Sheet 2011. (2011) Available at: http://www.familydocs.org/f/CDC%20Diabetes%20fact%20sheet-2011.pdf. (Accessed: 31st May 2016).
10. Berger, A. et al. Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids in Health and Disease. 3(2) (2004). doi: 10.1186/1476-511X-3-2.
11. Kanmatsuse. et al. Studies on Ganoderma lucidum efcacy against hypertension and side Effects. Journal of the Pharmaceutical Society of Japan. 105(10), 942-947 (1985).
12. Zhang, H. N. & Lin, Z. B. Effect and mechanism of Ganoderma lucidum polysaccharide on autoimmune diabetic mice. National Medical Journal of China. 83(22), 1999-2000 (2003).
13. Hikino, H., Konno, C., Mirin, Y. & Hayashi, T. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit bodies. Planta Medica. 4, 339-340 (1985).
14. Kimura, Y., Okuda, H. & Arichi, S. Effects of the extracts of Ganoderma lucidum on blood glucose level in rats. Planta Medica. 54(4), 290-294 (1988).
15. Liang, R. & Peng, K. Experimental studies on hypoglycaemic Effects and mechanisms of ganoderma spore extract in diabetic rats. Pharmacology and Clinics of Chinese Materia Medica. 14(5), 17-19 (1998).
16. Zhang, H. N., He, J. H., Yuan, L. & Lin, Z. B. In vitro and in vivo protective Effect of Ganoderma lucidum polysaccharides on alloxan-induced pacreatic islets damage. Life Sciences. 73(18), 2307-2319 (2003).
17. Zhang, H. N. & Lin, Z. B. Hypoglycemic Effect of Ganoderma lucidum polysaccharides. Acta Pharmacologica Sinica. 25(2), 191-195 (2004).
18. Yang, B., Jeong, S. & Song, C. Hypolipidemic Effect of exo-and endo-biopolymers produced from submerged mycelial culture of Ganoderma lucidum in rats. Journal of Microbiology and Biotechnology. 12(6), 872-877 (2002).
19. Kabir, Y., Kimura, S. & Tamura, T. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). Journal of Nutritional Science and Vitaminology. 34, 433-438 (1988).
20. Gao, Y. et al. A phase I/II study of ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with type 2 diabetes mellitus. International Journal of Medicinal Mushrooms. 6(1), 33-39 (2004b).
21. Gao, Y. et al. A phase I/II study of ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms. 6(4), 327-334 (2004a).
22. Wachtel-Galor, S., Szeto, Y. T., Tomlinson, B. & Benzie, I. F. Ganoderma lucidum ('ling zhi'): acute and short term biomarker response to supplementation. International Journal of Food Sciences and Nutrition. 55(1), 75-83 (2004b).
23. Jin, H. et al. Treatment of hypertension by ling zhi combined with hypotensor and its Effects on arterial, arteriolar and capillary pressure and microcirculation. In Microcirculatory approach to Asian traditional medicine: Strategy for the scientifc evaluation-Selected proceedings from the 2nd Asian Congress for Microcirculation (1996). (131-138). Amsterdam, New York: Elsevier.
24. Wang, C.-W., Tschen, J. S.-M. & Sheu, W. H.-H. Ganoderma lucidum on metabolic control in type 2 diabetes subjects: A double-blinded placebo control study. Journal of Internal Medicine Taiwan. 19, 15-60 (2008).
25. Winther, K., Mehlsen, J., Rein, E., Hansen, A. & Goino, T. A combination of Japanese ginseng, Ganoderma lucidum and trametes versicolor, referred to as the GOINO PROCEDURE, can lower blood glucose and LDL-cholesterol in patients with NIDDM. Atherosclerosis Suppl. 4, 339 (2003). doi: 10.1016/S1567-5688(03)91457-7.
26. Klupp. et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 17(2), CD007259. (2015).
27. Balon, T., Jasman, A. & Zhu, J.-S. A fermentation product of Cordyceps sinensis increases whole body insulin sensitivity in rats. Journal of Alternative and Complementary Medicine. 8(3), 315-323 (2002).
28. Bao, Z. D., Wu, Z. G. & Zheng, F. Amelioration of aminoglycoside nephrotoxicity by Cordyceps sinsensis in old patients. Journal of Integrated Traditional and Western Medicine. 14(5), 259, 271-274 (1994).
29. Chiou, W., Chang, P., Chou, C. & Chen, C. Protein constituent contributes to the hypotensive and vasorelaxant activities of Cordyceps sinensis. Life Sciences. 66(14), 1369-1376 (2000).
30. Kiho, T. et al. Polysaccharides in fungi 36: Hypoglycemic activity of a polysaccharide (CS-F30) from the cultural mycelium of Cordyceps sinensis and its Effect on glucose metabolism in mouse liver. Biological and Pharmaceutical Bulletin. 19(2), 294-296 (1996).
31. Kiho, T. et al. Structural features and hypoglycemic activity of a polysaccharide (CS-F10) from the cultured mycelium of Cordyceps sinensis. Biological and Pharmaceutical Bulletin. 22(9), 960-970 (1999).
32. Lo, H.-C., Tu, S.-T., Lin, K.-C. & Lin, S.-C. The antihyperglycemic activity of the fruiting body of Cordyceps in diabetic rats induced by nicotinamide and streptozotocin. Life Sciences. 74(23), 2897-2908 (2004).
33. Wojcikowski, K., Johnson, D. W. & Gobe, G. Medicinal herbal extracts: Renal friend or foe? Part two: Herbal extracts with potential renal benefts. Nephrology. 9(6), 400-405 (2004).
34. Yamaguchi, Y. et al. Inhibitory Effects of water extracts from fruiting dodies of cultured Cordyceps sinensis on raised serum lipid peroxide levels and aortic cholesterol deposition in atherosclerotic mice. Phytotherapy Research. 14(8), 650-652 (2000).
35. Zhao, C.-S. et al. CordyMaxTM Cs-4 improves glucose metabolism and increases insulin sensitivity in normal rats. Journal of Alternative and Complementary Medicine. 8(3), 309-314 (2002).
36. Zhu, J. S., Halpern, G. M. & Jones, K. The scientifc rediscovery of an ancient Chinese herbal medicine: Codyceps sinensis: Part 1. Journal of Alternative and Complementary Medicine. 4(3), 289-303 (1998).
37. Koh, J. H., Kim, J. M., Chang, U. J. & Suh, H. J. Hypocholesterolemic Effect of hot-water extract from mycelia of Cordyceps sinensis. Biological and Pharmaceutical Bulletin. 26(1), 84-87 (2003).
38. Shao, G. et al. Clinic report of cultured Cordyceps treating hyperlipidaemia. Chinese Journal of Integrated Traditional and Western Medicine. 5(11), 652-654 (1985).
39. Xu, N. S. & Zhang, B. Q. Effect of Cordyceps on plasma lipids in normal, stress and hyperlipidaemia rates. Chinese Journal of Pathophysiology. 3(4), 215-219 (1987).
40. McGufn, M., Hobbs, C., Upton, R. & Goldberg, A. American Herbal Products Association's botanical safety handbook. Boca Raton, US: CRC Press (1997).
41. nd edn.). Boca Raton, US: CRC Press (2000).
42. Teow, S. Effective dosage of the extract of Ganoderma lucidum in the treatment of various ailments. In Royse (Ed.), Mushroom biology and mushroom products (1996). Pennsylvania: Pennsylvania State University.
43. Chen, X. et al. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. International Immunopharmacology. 6(3), 499-508 (2005).
44. Wachtel-Galor, S., Tomlinson, B. & Benzie, I. F. Ganoderma lucidum ('ling zhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. British Journal of Nutrition. 91(2), 263-269 (2004a).
45. Gao, Y. et al. A randomised, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr) Lloyd (Aphyllophoromycetideae) polysaccharides (Ganapoly) in patients with advanced lung cancer. International Journal of Medicinal Mushrooms. 5(4), 369-381 (2003).
46. Gao, Y. et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune funtions of patients with advanced lung cancer. Journal of Medicinal Food. 8(2), 159-168 (2005).
47. Gao, Y. et al. A phase I/II study of a Ganoderma lucidum (Curt.:Fr.) P. Karst. Extract (Ganapoly) in patients with advanced cancer. International Journal of Medicinal Mushrooms. 4(3), 207-214 (2002).
48. Gau, J., Lin, C., Lee, S. & Wang, S. The lack of antiplatelet Effect of crude extracts form Ganoderma lucidum on HIV-positive hemophiliacs. American Journal of Chinese Medicine. 18(3-4), 175-179 (1990).
49. Kwok, Y. et al. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic Effects of Ganoderma lucidum (ling zhi) in healthy volunteers. Anesthesia and Analgesia. 101(2), 423-426 (2005).
50. Tang, W. et al. A randomised, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of Medicinal Food. 8(1), 53-58 (2005).
51. Wicks, S. M. et al. Safety and tolerability of Ganoderma lucidum in healthy subjects: A double-blind randomized placebo-controlled trial. American Journal of Chinese Medicine. 35(3), 407-414 (2007).
52. Yuen, M.-F., Ip, P., Ng, W.-K. & Lai, C.-L. Hepatotoxicity due to a formulation of Ganoderma lucidum (ling zhi). Journal of Hepatology. 41, 686-687 (2004).
53. National Prescribing Service, National consumer survey 2008: Final report. (2008) Available at: http://www.nps.org.au/about-us/what-we-do/our-research/complementary-medicines/nps-consumer-survey-cms-use-fndings. (Accessed: 31st May 2016).
54. Williamson, M. et al. Information use and needs of complimentary medicine users (2008). (1-78). Sydney: National Precribing Service.
55. Grant, S. J., Bin, Y. S., Kiat, H. & Chang, D. H. The use of complementary an alternative medicine by people with cardiovascular disease: a systematic review. BMC Public Health. 12, 299 (2012).
56. Kiat, H., Bin, Y. S., Grant, S. & Chang, D. H. Complmentary medicine use in cardiovascular disease: a clinician's viewpoint. Med J Aust. 19, 654-656 (2011).
57. National Institute of Complementary Medicine, Health Economics of Complementary Medicine. (2016) Available at: http://nicm.edu. au/health-information/health-economics. (Accessed: 31st May 2016).
58. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials. 17, 1-12 (1996).
59. Maher, C. G. et al. Reliability of the PEDro scale for rating quality of randomized controlled trials. Physical Terapy. 83(8), 713-721 (2003).
60. Higgins, J. P. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal. 343, d5928 (2011). doi: 10.1136/bmj.d5928.
61. Hill-Briggs, F., Gary, T. L., Baptiste-Roberts, K. & Brancati, F. L. Tirty-six-item short form outcomes following a randomized controlled trial in type 2 diabetes. Diabetes Care. 28(2), 443-444 (2005).
62. Bacchetti, P. Current sample size conventions: faws, harms, and alternatives. BMC Medicine. 8, 17-17, doi: 10.1186/1741-7015-8-17 (2010).